"Postmarketing experience:
Reproductive System: sexual dysfunction that continued after discontinuation of treatment, including erectile dysfunction, libido disorders, ejaculation disorders, and orgasm disorders; male infertility and/or poor seminal quality (normalization or improvement of seminal quality has been reported after discontinuation of finasteride); testicular pain."
It's the first time FDA admits infertility problems and orgasm disorders related to Propecia The FDA also advises that they have started the process of notifying health care professionals who prescribe Finasteride (dermatologists, physicians, urologists and residents) on the revision and label changes.
To read the full article on the FDA website:
http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm299754.htm
Propecia precribing information:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020788s020s021s023lbl.pdf